

I hereby certify that this correspondence is being electronically filed in the United States Patent and Trademark Office on 15 April 2008.

Barbara S. Kitchell
Barbara S. Kitchell, Ph.D. Patent Attorney

REQUEST FOR CERTIFICATE OF CORRECTION UNDER 37 CFR 1.322
Examining Group 1647
Patent Application
Docket No. UF-530XT
Patent No. 7,291,710

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ronald L. Hayes, Ka-Wang (Kevin) Wang, Brian R. Pike
Issued : November 6, 2007
Patent No. : 7,291,710
For : Detection of Spectrin and Spectrin Proteolytic Cleavage Products in Assessing Nerve Cell Damage

Mail Stop Certificate of Corrections Branch
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CERTIFICATE OF CORRECTION
UNDER 37 CFR 1.322 (OFFICE MISTAKE)

Sir:

A Certificate of Correction for the above-identified patent has been prepared and is attached hereto.

In the left-hand column below is the column and line number where the error occurred in the patent. In the right-hand column is the page and line number in the application where the correct information appears.

Patent Reads:

Column 3, line 25:

“SBDP1150”

Application Reads:

Page 4, line 10:

--SBDP150--.

A true and correct copy of page 4 of the specification as filed, which support Applicants' assertion of the error on the part of the Patent Office, accompanies this Certificate of Correction.

The Commissioner is also authorized to charge any fees as required under 37 CFR 1.20(a) to Deposit Account No. 19-0065.

Approval of the Certificate of Correction is respectfully requested.

Respectfully submitted,



Barbara S. Kitchell, Ph.D.
Patent Attorney
Registration No. 33,928
Phone No.: 352-375-8100
Fax No.: 352-372-5800
Address: P.O. Box 142950
Gainesville, FL 32614-2950

BSK/dc/lkw

Attachments: Copy of page 4 of the specification
Certificate of Correction

spectrin and an α II SBDP generated from proteolytic cleavage of α II spectrin by at least one protease selected from the group consisting of caspase-3 and calpain; and (c) printed instructions for reacting the agent with the biological sample or a portion of the biological sample to detect the presence or amount of the at least one marker in the biological sample.

In the kit, the marker(s) being assessed can be one or more of α II spectrin, SBDP150i, SBDP150, SBDP145, and SBDP120. The agent can be one that does not specifically bind at least one of α II spectrin, SBDP150i, SBDP150, SBDP145, and SBDP120; or one that specifically binds only one of α II spectrin, SBDP150i, SBDP150, SBDP145, and SBDP120. The kit can also include a detectable label such as one conjugated to the agent, or one conjugated to a substance that specifically binds to the agent.

As used herein, "bind," "binds," or "interacts with" means that one molecule recognizes and adheres to a particular second molecule in a sample, but does not substantially recognize or adhere to other structurally unrelated molecules in the sample. Generally, a first molecule that "specifically binds" a second molecule has a binding affinity greater than about 10^5 to 10^6 moles/liter for that second molecule.

By reference to an "agent that specifically binds" another molecule is meant any substance that binds the other molecule, and displays no substantial binding to other naturally occurring proteins other than those sharing the same antigenic determinants as other molecule. Examples of such agents include antibodies and aptamers.

The term "antibody" includes polyclonal and monoclonal antibodies as well as antibody fragments or portions of immunoglobulin molecules that can specifically bind the same antigen as the intact antibody molecule.

As used herein, a "detectable label" is meant any substance that can be detected either directly or indirectly.

By the phrase "conjugated to" is meant covalently or non-covalently bonded to or otherwise physically associated with.

Unless otherwise defined, all technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention,

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

PATENT NO. : 7,291,710 Page 1 of 1

APPLICATION NO.: 10/660,069

DATED : November 6, 2007

INVENTORS : Ronald L. Hayes, Ka-Wang (Kevin) Wang, Brian R. Pike

It is certified that an error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 3,

Line 25, "SBDP1150" should read --SBDP150--.

MAILING ADDRESS OF SENDER:
Saliwanchik, Lloyd & Saliwanchik
P.O. Box 142950
Gainesville, FL 32614-2950